Why is Health Canada only letting doctors and the public know part of the story about the safety and effectiveness of new pharmaceutical drugs? Inadequate information can be as dangerous as misinformation. Here's how.
Roojin Habibi is an MSc candidate in McMaster University’s Global Health program, and a Research Fellow at the Pharmaceutical Policy Research Collaboration (PPRC).
SUBSCRIBE AND FOLLOW